Skip to main content

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers

Cancer Chemotherapy and Pharmacology volume 57, pages 465–474 (2006)Cite this article

Abstract

Purpose: To determine the maximum tolerated dose and dose-limiting toxicity (DLT) of the novel anticancer agent, motexafin gadolinium (MGd), administered concurrently with radiation therapy (RT) in patients with locally advanced pancreatic or biliary tumors. The pharmacokinetics of MGd were also evaluated. Methods: Cohorts of three to six patients were treated with escalating doses of MGd, administered three times per week for a total of 16 doses concurrent with RT. The dose of RT was fixed at 5,040 cGy, and given in 28 fractions, from Monday to Friday of every week. Plasma MGd concentrations were measured by high performance liquid chromatography. Results: Eight patients were treated at dose level 1 (2.9 mg/kg), with one DLT (grade 3 fever). Three patients were treated at dose level 2 (3.6 mg/kg), and two DLTs were noted. One DLT was grade 3 nausea and vomiting (N/V), and the other was grade 3 skin toxicity. The most common toxicity was N/V. There were no objective responses. The median survival was 6 months. The MGd plasma concentration versus time profile in each patient was best fit by a two-compartment, open, linear model. There was minimal accumulation of MGd in plasma with the three-times/week dosing schedule. Simulation of the time course of MGd in the peripheral compartment indicated that maximal MGd concentrations of 1–2 μmol/kg occurred between 4 and 6 h after MGd infusion. Conclusion: Dose level 1 (2.9 mg/kg of MGd) is the recommended dose for combination with (RT) in phase II studies for locally advanced pancreatic and biliary cancers. Patient tolerance might be improved by modification of the RT schedule and antiemetic prophylaxis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Moertel CG, Frytak S, Hahn RG, O’Connell MJ et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710

    PubMed  Article  CAS  Google Scholar 

  2. Anonymous (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80:751–755

    Article  Google Scholar 

  3. Crane CH, Abbruzzese JL, Evans DB et al (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52:1293–1302

    Article  PubMed  CAS  Google Scholar 

  4. Muler J, McGinn C, Normolle D, Lawrence T, Brown D, Hejna G, Zalupski M (2004) Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 22:238–243

    Article  PubMed  CAS  Google Scholar 

  5. Safran H, Dipetrillo T, Iannitti D et al (2002) Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial. Int J Radiat Oncol Biol Phys 54:137–141

    Article  PubMed  CAS  Google Scholar 

  6. McGinn C, Zalupski M, Shureiqi I et al (2001) Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202–4208

    PubMed  CAS  Google Scholar 

  7. Rich T, Harris J, Abrams R et al (2004) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. J Clin Oncol 27:51–56

    Article  CAS  Google Scholar 

  8. Erickson BA, Nag S (1998) Biliary tree malignancies. J Surg Oncol 67:203–210

    Article  PubMed  CAS  Google Scholar 

  9. Miller RA, Woodburn K, Fan Q et al (1999) In vivo animal studies with gadolinium(III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 45:981–989

    Article  PubMed  CAS  Google Scholar 

  10. Sessler JL, Miller RA (2000) Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 59:733–739

    Article  PubMed  CAS  Google Scholar 

  11. Magda D, Lepp C, Gerasimchuk N et al (2001) Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 51:1025–1036

    Article  PubMed  CAS  Google Scholar 

  12. Young SW, Quing F, Harriman A et al (1996) Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 93:6610–6615

    Article  PubMed  CAS  Google Scholar 

  13. Carde P, Timmerman R, Mehta MP et al (2001) Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074–2083

    PubMed  CAS  Google Scholar 

  14. Mehta MP, Shapiro WR, Glantz MJ (2002) Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445–3453

    Article  PubMed  CAS  Google Scholar 

  15. Rosenthal DI, Nurenberg P, Becerra CR (1999) A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5:739–745

    PubMed  CAS  Google Scholar 

  16. Mehta MP, Rodrigus P, Terhaard CHJ et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21:2529–2536

    Article  PubMed  CAS  Google Scholar 

  17. Meyers CA, Smith JA, Bezjak A et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157–165

    Article  PubMed  CAS  Google Scholar 

  18. Pharmacyclics Corporation (2004) Investigators brochure for Motexfin gadolinium

  19. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    PubMed  Article  CAS  Google Scholar 

  20. Parise RA, Miles DR, Egorin MJ (2000) Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma. J Chromatogr B Biomed Sci Appl 749:145–152

    Article  PubMed  CAS  Google Scholar 

  21. D’Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115–134

    Article  PubMed  CAS  Google Scholar 

  22. Akaike H (1979) A Bayesian extension of the minimal AIC procedures of autoregressive model fitting. Biometrika 66:237–242

    Article  Google Scholar 

  23. Miles DR, Smith JA, Phan SC et al (2005) Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme. J Clin Pharm 45:299–312

    Article  CAS  Google Scholar 

  24. Miller RA, Fan Q, Lee I et al (2002) Motexafin gadolinium (MGd) increases tumor response to chemotherapy in Lewis lung cancer (LLC) animal model. Proc Am Soc Clin Oncol 21: (Abstract#466)

  25. Magda D, Lepp C, Fan Q et al (2003) The redox mediator motexafin gadolinium (MGd) enhances the activity of several chemotherapy drugs. Proc Am Soc Clin Oncol 23:229 (Abstract#917)

    Google Scholar 

  26. Ramnath N, Chatta G, Egorin MJ, Phan S, Creaven PJ (2004) A phase 1 trial of motexafin gadolinium and docetaxel for advanced solid tumors. Proc Am Soc Clin Oncol 22: (Abstract#3171)

  27. Thomas JP, Ramanathan RK, Wilding G et al (2003) A phase I study of motexafin gadolinium (MGd) in combination with doxorubicin (Dox). Proc Am Soc Clin Oncol 22:227 (Abstract#909)

    Google Scholar 

  28. Evens AM, Lecane P, Magda D et al (2005) Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105:1265–1273

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Ms. Alicia Depastino and Mr. Jeremy Hedges for excellent secretarial support and the UPCI Hematology/Oncology Writing Group for constructive criticisms regarding this manuscript. This study was sponsored by the Cancer Therapy and Evaluation Program of the National Cancer Institute, Bethesda, MD, USA. Presented, in part, at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, 2001. Supported, in part, by grants UO1-CA69855, P30CA47904, NIH/NCCR/GCRC#5M01 RR 00056 to the University of Pittsburgh Cancer Institute and Medical Center. U01-CA069852-11 to University of Chicago Medical Center, NIH grants K24 CA84081 and P30CA23108 to Dartmouth College and U01-CA62491/CA/NCI to the University of Wisconsin Comprehensive Cancer Center.

Author information

Author notes

  1. Marwan Fakih & Donald L. Trump

    Present address: Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA

  2. Sridhar Mani

    Present address: Montefiore Medical Ctr, 1825 East Chester Rd, Rm 2S-49, Bronx, NY, 10461, USA

Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA

    Ramesh K. Ramanathan, Marwan Fakih, Donald L. Trump, Chandra P. Belani & Merrill J. Egorin

  2. Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA

    Ramesh K. Ramanathan, Marwan Fakih, Julie L. Eiseman, Donald L. Trump, Chandra P. Belani, Robert A. Parise & Merrill J. Egorin

  3. Division of Hematology/Oncology, Department of Medicine, University of Chicago School of Medicine, Chicago, IL, 60637, USA

    Sridhar Mani

  4. Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA

    Melvin Deutsch

  5. Molecular Therapeutics Research Program, Norris Cotton Cancer Center, Dartmouth-Hitchock Medical Center, Lebanon, NH, 03756, USA

    Raymond P. Perez

  6. Department of Human Oncology, University of Wisconsin School of Medicine, Madison, WI, 53792, USA

    Mark A. Ritter

  7. Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA

    Julie L. Eiseman & Merrill J. Egorin

  8. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Centers, National Cancer Institute, Bethesda, MD, 20892, USA

    S. Percy Ivy

  9. Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA

    Douglas M. Potter

  10. UPMC Cancer Pavilion, # 562, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA

    Ramesh K. Ramanathan

Authors
  1. Ramesh K. Ramanathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marwan Fakih
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sridhar Mani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melvin Deutsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raymond P. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mark A. Ritter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julie L. Eiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Percy Ivy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Donald L. Trump
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chandra P. Belani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Robert A. Parise
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Douglas M. Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Merrill J. Egorin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramesh K. Ramanathan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ramanathan, R.K., Fakih, M., Mani, S. et al. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol 57, 465–474 (2006). https://doi.org/10.1007/s00280-005-0071-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0071-y

Keywords

  • Phase I study
  • Motexafin gadolinium
  • Radiation therapy
  • Pancreatic cancer